This Article Abstract Full Text (PDF) All Versions of this Article: 34/3/671    most recent 01.STR.0000057976.53301.69v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vila, N. Articles by Chamorro, A. Search for Related Content PubMed PubMed Citation Articles by Vila, N. Articles by Chamorro, A. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Stroke Related Collections Acute Cerebral Infarction Growth factors/cytokines Cerebral Lacunes

(Stroke. 2003;34:671.)
© 2003 American Heart Association, Inc.

Original Contributions

Levels of Anti-Inflammatory Cytokines and Neurological Worsening in Acute Ischemic Stroke

Nicolás Vila, MD; José Castillo, MD; Antonio Dávalos, MD; Anna Esteve, PhD; Anna M. Planas, PhD Ángel Chamorro, MD

From the Hospital Clínic (N.V., A.C.), Clinical Institute of Nervous System Diseases, Instituto Investigaciones Biomédicas August Pi i Sunyer, Barcelona; Hospital Clínic Universitario (J.C.), Santiago de Compostela; Hospital Universitario Doctor Josep Trueta (A.D.), Girona; Centre Estudis Epidemiològics sobre la SIDA de Catalunya (A.E.), University Hospital Germans Trías i Pujol, Badalona; and Department of Pharmacology and Toxicology (A.M.P.); Instituto Investigaciones Biomédicas Consejo Superior Investigaciones Científicas, Barcelona, Spain.

Correspondence to Ángel Chamorro, MD, Clinical Institute of Nervous System Diseases, IDIBAPS, Hospital Clínic, Villaroel 170, 08036 Barcelona, Spain. E-mail chamorro{at}medicina.ub.es

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background— Mechanisms involved in stroke progression are incompletely understood. Ischemic brain injury is characterized by acute local inflammatory response mediated by cytokines. Anti-inflammatory cytokines act in a feedback loop to inhibit continued proinflammatory cytokine production. We assessed the implication of interleukin (IL)-10 and IL-4 in deteriorating ischemic stroke.

Methods— Two hundred thirty-one patients with ischemic stroke within the first 24 hours from onset were included. Neurological worsening was defined when the Canadian Stroke Scale score fell at least 1 point during the first 48 hours after admission. Anti-inflammatory cytokines were determined in plasma obtained on admission.

Results— Eighty-three patients (35.9%) worsened within the first 48 hours after stroke onset. Significantly lower concentrations of IL-10 were found in patients with neurological worsening (P<0.05), but IL-4 levels were similar in patients with or without deterioration. Lower plasma concentrations of IL-10 (<6 pg/mL) were associated with clinical worsening on multivariate analysis (odds ratio=3.1, 95% CI=1.1 to 8.9) independently of hyperthermia, hyperglycemia, or neurological condition on admission. Further analysis disclosed that early worsening was independently associated with lower IL-10 plasma levels in patients with subcortical infarcts or lacunar stroke but not in patients with cortical lesions.

Conclusions— Anti-inflammatory cytokine IL-10 is associated with the early clinical course of patients with acute ischemic stroke, especially in patients with small vessel disease or subcortical infarctions.

Key Words: cytokines • inflammation • interleukin-4 • interleukin-10 • neuroprotection • stroke, ischemic

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
One third of patients with acute ischemic stroke develop early neurological worsening, a situation associated with increased mortality and long-term functional disability.^1,2 The underlying basic mechanisms involved are not completely understood, although biochemical factors have been suggested.^1,2 Cerebral ischemia evokes an inflammatory response characterized by activation and release of cytokines, chemokines, endothelial-leukocyte adhesion molecules, and proteolytic enzymes that exacerbate tissue damage.^3,4 Increased production of proinflammatory cytokines and chemokines has been detected in experimental models of brain ischemia as well in patients with acute stroke.^3,4 Moreover, increased levels of proinflammatory cytokines are related to a greater extent of cerebral infarct and poorer clinical outcome in patients with ischemic stroke.^4–6

Ischemic tissue damage can be reduced in experimental models with a variety of anti-inflammatory agents including antibodies against adhesion molecules, neutrophil depletants, inhibitors of proinflammatory cytokines, and anti-inflammatory cytokines.^7–10 Interleukin (IL)-10 and IL-4 are anti-inflammatory molecules, mainly secreted by lymphocytes and monocytes/macrophages, that block proinflammatory actions.¹¹ IL-10 and IL-4 may provide a negative feedback mechanism to limit production of proinflammatory cytokines in ischemic stroke. Administration of IL-10^8,10 or gene transfer⁹ in experimental models of focal brain ischemia reduces infarct volume, suggesting that it may have neuroprotective effects.^8–10 In patients with acute stroke, a transient increase in IL-10 concentrations in plasma, cerebrospinal fluid (CSF), and blood mononuclear cells have been detected.^12–14 Moreover, low levels of IL-10 have been associated with an unstable clinical course in patients with angina.¹⁵ Therefore, in this prospective study we evaluated whether plasma concentrations of anti-inflammatory cytokines (IL-10 and IL-4) are associated with early worsening of neurological symptoms in patients with acute ischemic stroke.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
From a cohort of 249 consecutive patients with first-ever acute ischemic stroke admitted within 24 hours of the onset of symptoms in a prospective investigation evaluating factors related to stroke deterioration, a group of 231 patients who had available stored plasma samples were evaluated in the present secondary analysis. To avoid the confounding effect on inflammatory markers, subjects with inflammatory or infectious diseases, cancer, hematological diseases, or severe renal or liver failure were not included in the study. The protocol was approved by the local Ethics Committee, and the methodology was described previously.^1,6 Briefly, patients were admitted to neurological wards and managed according to evidence-based stroke guidelines. Thrombolytics, hemodilution, corticosteroids, or nimodipine were not permitted. Antiplatelet drugs were used in atherothrombotic and lacunar infarcts and anticoagulants in suspected cardioembolic infarcts when cranial CT scan and clinical examination did not suggest a large cerebral lesion. Stroke subtype was classified according to TOAST definitions.¹⁶ Stroke severity was scored on admission and after 48 hours by the same neurologist using the Canadian Stroke Scale (CSS).¹⁷ The CSS measures level of consciousness; aphasia; orientation; facial paresis; and power in arm, hand, and leg on a score from 1.5 (maximum deficit) to 10 (absence of deficit). Stroke with neurological deterioration was diagnosed when the CSS score dropped at least 1 point in the second neurological examination.^1,6 We used this cutoff value because a decrease in 1 point or an increase in 1 point in the CSS between the first 24 and 48 hours after acute stroke is clinically relevant in terms of 30-day mortality and disability using the Barthel Index.¹⁸ Patients whose condition worsened exclusively in the area of orientation or who remained stable or improved in the same period were classified as nonworsening.¹ On admission, body temperature and blood pressure were recorded. Then, chemistry, basic hematology, chest X-rays, electrocardiography, and non-enhanced brain CT scan were performed. Early CT signs of infarction on admission were assessed in all instances by a neuroradiologist blinded to clinical and laboratory data. Between days 4 and 7 after clinical onset a second nonenhanced brain CT scan was performed to calculate infarct volume and to classify the final infarct subtype and topography. Methods to calculate infarct volume and infarct topography definitions were previously reported.^6,19

For cytokine determination, blood samples of patients were collected on admission in tubes with potassium edetate, centrifuged at 3000g for 5 minutes, and immediately frozen and stored until analysis (5 to 7 years at -80°). Mean admission delay from stroke onset was 8.2±5.7 hours (range=1.5 to 23 hours). Samples were collected within 12 hours in 80% of patients and within 6 hours in 50%. Samples were also obtained in 43 patients admitted without neurological disorders (29 men and 21 women; mean age 56±17 years). Plasma concentrations of IL-10 and IL-4 were measured with a commercially available quantitative immunoassay (Quantikine) obtained from R&D Systems. The minimum detectable doses for human IL-10 and IL-4 provided by the manufacturer were 0.5 and 10 pg/mL, respectively. Cytokine determinations were done blinded to clinical and radiological data.

For statistical analyses, the ² test, the Student t test, and the Mann-Whitney test were used as appropriate. Stroke deterioration was assessed by stepwise logistic regression analysis entering into the model all variables with probability value 0.10 on univariate testing, which included IL-10, body temperature, fasting serum glucose, fibrinogen, total leukocyte count, baseline CSS, admission delay, and presence of early infarct signs on brain CT scan. Continuous variables without normal distribution were analyzed after their logarithmic transformation. Cutoff values for plasma IL-10 were calculated as described by Robert et al²⁰ given the different distribution of IL-10 according to outcome groups. Odds ratios and 95% confidence intervals were calculated from ß coefficients and their SEs. A probability value <0.05 was established as statistically significant.

	Results

Top Abstract Introduction Methods Results Discussion References

 
In 69 patients (29.9%), no changes were detected in the CSS score. Seventy-nine patients (34.2%) improved their CSS score, as follows: 54 (23.4%) by 1 point, 21 (9.1%) by 2 points, and 4 by 3 points. Eighty-three (35.9%) patients worsened their CSS score within the first 48 hours after stroke onset, as follows: 41 (17.7%) by 1 point, 24 (10.4%) by 2 points, and 18 (7.8%) by 3 points. The main characteristics of the studied population are shown in Table 1. Patients with early stroke deterioration had a slightly longer delay to hospital admission and higher baseline glucose, fibrinogen, and body temperature compared with patients with a stable clinical course. However, the two clinical groups disclosed similar stroke subtypes and degree of neurological impairment on admission.

View this table: [in this window] [in a new window]   TABLE 1. Main Characteristics of Study Population

Although plasma concentrations of IL-10 were not different between control group (5.9±1.6 pg/mL) and stroke patients (6.0±2.2 pg/mL), IL-10 levels were significantly higher in those stroke patients who remained stable or improved during the first 48 hours than in patients with clinical deterioration (6.2±2.2 pg/mL versus 5.6±2.0 pg/mL; P<0.05) (Figure 1). However, concentrations of IL-4 were similar in both outcome groups (21.2±5.3 versus 20.3±5.5 pg/mL).

View larger version (29K): [in this window] [in a new window]   Figure 1. IL-10 plasma levels (pg/mL) and neurological worsening according to stroke topography. Patients with neurological worsening had significantly reduced levels of IL-10 in plasma compared with patients without neurological worsening only in subcortical infarcts n=99) (P<0.01) but not in cortical infarcts (n=77).

As shown in Table 2, the following variables remained on multivariate analysis independently associated with clinical worsening: IL-10 <6 pg/mL in plasma, body temperature, admission CSS, and serum glucose. Overall, levels of IL-10 were similar in patients with cortical and subcortical infarcts (Table 3). However, significantly lower IL-10 levels were detected in patients with subcortical infarcts who deteriorated compared with patients with subcortical infarcts who remained stable or improved (5.3±1.0 versus 6.1±0.5 pg/mL; P<0.05). Behavior of IL-10 levels was similar in cortical infarcts, but differences did not achieve statistical significance. In addition, similar levels of IL-4 were found in patients with and without worsening in both cortical and subcortical infarcts.

View this table: [in this window] [in a new window]   TABLE 2. Factors Associated to Neurological Deterioration

View this table: [in this window] [in a new window]   TABLE 3. Levels of Interleukin-10 (IL-10) According to Infarct Topography and Stroke Subtypes

Table 3 also shows that levels of IL-10 were not different between stroke subtypes. Figure 2 represents IL-10 levels and stroke progression in relation to stroke subtypes. Levels of IL-10 were lower in patients with deterioration in all subgroups. However, significant differences between plasma IL-10 levels and stroke worsening were only detected in patients with lacunar infarcts. Those patients with lacunar infarcts that deteriorated had lower levels of IL-10 compared with those with infarcts that remained stable or improved (5.3±1.2 versus 6.5±0.9 pg/mL; P<0.01). No differences in levels of IL-4 were found in patients with and without worsening according to stroke subtypes.

View larger version (32K): [in this window] [in a new window]   Figure 2. IL-10 plasma levels (pg/mL) and neurological worsening according to stroke etiology. Patients with neurological worsening had significant lower concentrations of IL-10 in plasma than patients without neurological worsening only in the subgroup of lacunar infarcts (P<0.01). LAC indicates lacunar infarct (n=33); ATH, atherosclerotic infarct (n=84); CEMB, cardioembolic infarct (n=76); and IUC, infarct of undetermined cause (n=38).

Finally, in 61 patients with nonlacunar infarcts and subcortical topography, small but significant lower plasma concentrations of IL-10 were detected in subjects with early neurological deterioration (n=16) compared with those with stable or improved course (n=45) (5.2±2.4 versus 5.8±2.0 pg/mL; P=0.05).

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
IL-10 is one of the anti-inflammatory cytokines that may regulate the complex network of reactions that occur in acute cerebral ischemia. In the present study, lower levels of IL-10 in plasma measured within 24 hours from stroke onset were significantly associated with early deterioration of neurological symptoms in patients with ischemic stroke. This relation was independent of other well-known predictors of clinical worsening such as clinical severity on admission, hyperglycemia, and early CT signs of infarction or hyperthermia. In humans, increased concentrations of IL-10 are found shortly after stroke onset in CSF and plasma, reaching the highest level between days 3 and 7.^12,14 In addition, patients with acute stroke have increased IL-10 secreting monocytes in peripheral blood compared with controls.¹³ Contrarily, we did not find differences in IL-4 levels in patients with or without neurological deterioration. These results suggest that IL-4, despite its inhibitory capacity on proinflammatory cytokines, is less important than IL-10 in acute ischemic stroke. In agreement with this finding, Pelidou et al¹³ also failed to demonstrate differences in IL-4–secreting monocytes in patients with stroke compared with controls.

The present study also shows an association between lower levels of IL-10 with neurological deterioration in subcortical and lacunar infarcts. These findings give further support to previous observations linking cytokines with early motor impairment in patients with lacunar stroke.⁶ Previously, we had reported that lacunar stroke might result from genetic susceptibility to inflammation-mediated damage in concert with atherosclerotic risk factors.²¹ A relationship between proinflammatory cytokines,²² excitatory amino acids,²³ and neurological worsening in lacunar infarcts were also found. Increase in infarct volume, as demonstrated with diffusion MRI, has been proposed as the main cause of neurological deterioration in lacunar infarcts,²⁴ as the likely result of delayed excitotoxic and inflammatory neuronal death. Thus, if these findings are validated, patients with lacunar infarcts would represent ideal candidates to participate in clinical trials of neuroprotection using anti-inflammatory drugs or inhibitors of excitotoxicity. In addition, these biological markers might be useful in the future to detect those patients with lacunar stroke at risk of motor deterioration, especially when this stroke subtype is the major cause of progressive motor deficits.²⁵

A direct implication of IL-10 in the pathophysiology of ischemic neurological deterioration cannot be extrapolated from our results as the levels of anti-inflammatory cytokines were not determined exactly at the moment of neurological deterioration. As well, these results must be interpreted with caution given that plasma concentrations of cytokines do not necessarily reflect the activity of cytokines within the central nervous system. Also, we recognize that we have not explored the potential effect of cytokines on late worsening. However, a body of experimental evidence^{8–10, 15, 26–27} implicates this anti-inflammatory cytokine in the downregulation of deleterious actions of proinflammatory cytokines. IL-10 inhibits monocyte/macrophage synthesis of IL-6 and tumor necrosis factor- by blocking gene transcription and downregulates release of intercellular adhesion molecule-1 (ICAM-1) and matrix metalloproteinase (MMP).^27–29 Animals deficient in IL-10 gene exhibited larger infarcts; increased neutrophil infiltration; and raised levels of tumor necrosis factor-, ICAM-1, MMP-2, and MMP-9.^27–29 Additionally, IL-10 may have neuroprotective activities resulting from other non–anti-inflammatory actions. This cytokine regulates apoptotic proteins detected in CSF after human brain ischemia,³⁰ modulates neuronal vulnerability to excitotoxic ischemic damage,²⁶ and inhibits the inducible form of NO synthase (iNOS).³¹ IL-10–deficient mice also developed increased levels of iNOS compared with the wild type.^26,31 Levels of excitotoxic amino acids,¹ NO products,³² proinflammatory cytokines,^3–6 and MMP³³ in plasma or in CSF have also been related with clinical outcome in human stroke. Contrarily, in hemorrhagic stroke it seems that anti-inflammatory cytokines do not play the same role as in cerebral ischemia.³⁴ Recently, levels of IL-10 and IL-4 were found to be unrelated to clinical outcome in patients with cerebral hemorrhages.³⁴

If levels of IL-10 are markers of neurological deterioration, an important issue is to determine why stroke patients may exhibit a different anti-inflammatory profile. Recently, several functional IL-10 gene polymorphisms have been described in the population.³⁵ Those patients with a specific IL-10 gene polymorphism, that determine low levels of IL-10, may be at risk to develop unstable vascular syndromes. A recent work demonstrated a relationship between low levels of IL-10 in plasma and the subsequent risk of stroke and also with mortality when the stroke occurs.³⁶ If this association is confirmed, those subjects genetically predisposed might be treated with exogenous IL-10 to prevent stroke and clinical worsening in acute stroke. Recombinant human IL-10 administered by intravenous injection in healthy volunteers is well tolerated and safe.³⁷ Thus, in addition to potential indications of IL-10 in chronic inflammatory diseases under current evaluation, this study gives additional evidence that IL-10 may have a potential role as neuroprotectant in acute vascular syndromes.

	Acknowledgments

 
We thank Jordi Casabona (CEESCAT, University Hospital Germans Trías i Pujol, Badalona, Spain) for statistical data management.

Received April 17, 2002; revision received September 25, 2002; accepted September 27, 2002.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Castillo J, Davalos A, Noya M. Progression of ischemic stroke and excitotoxic aminoacids. Lancet. 1997; 349: 79–83.[CrossRef][Medline] [Order article via Infotrieve]
2. Dávalos A, Toni D, Iweins F, Lesaffre E, Bastianello S, Castillo J. Neurological deterioration in acute ischemic stroke: potential predictors and associated factors in the European Cooperative Acute Stroke Study (ECASS) I. Stroke. 1999; 30: 2631–2636.[Abstract/Free Full Text]
3. Beamer NB, Coull BM, Clark WM, Hazel JS, Silberger JR. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann Neurol. 1995; 37: 800–804.[CrossRef][Medline] [Order article via Infotrieve]
4. Fassbender K, Rossol S, Kammer T, Daffertshofer M, Wirth S, Dollman M, Hennerici M. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci. 1994; 22: 135–139.
5. Tarkowski E, Rosengren L, Blomstrand C, Wikkelsö C, Jensen C, Ekholm S, Tarkowski A. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke. 1995; 26: 1393–1398.[Abstract/Free Full Text]
6. Vila N, Castillo J, Davalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. 2001; 31: 2325–2329.
7. Clark WM, Zivin JA. Antileukocyte adhesion therapy: preclinical trials and combination therapy. Neurology. 1997; 49 (suppl 4): S32–S38.[Medline] [Order article via Infotrieve]
8. Spera PA, Ellison JA, Feuerstein GZ, Barone FC. IL-10 reduces rat brain injury following focal stroke. Neurosci Lett. 1998; 251: 189–192.[CrossRef][Medline] [Order article via Infotrieve]
9. Ooboshi H, Ibayashi S, Kitazono T, Yao H, Fujishima M, Iida M. Postischemic gene transfer of IL-10 protects against focal ischemia. Stroke. 2002; 33: 346.
10. Dietrich WD, Busto R, Bethea JR. Postischemic hypothermia and IL-10 treatment provide long-lasting neuroprotection of CA1 hippocampus following transient global ischemia in rats. Exp Neurol. 1999; 158: 444–450.[CrossRef][Medline] [Order article via Infotrieve]
11. Tedgui A, Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ Res. 2001; 88: 877–887.[Abstract/Free Full Text]
12. Tarkowski E, Rosengren L, Blomstrand C, Wikkelsö C, Jensen C, Ekholm S, Tarkowski A. Intrathecal release of pro- and anti-inflammatory cytokines during stroke. Clin Exp Immunol. 1997; 110: 492–499.[CrossRef][Medline] [Order article via Infotrieve]
13. Pelidou SH, Kostulas N, Matusevicius D, Kivisäkk P, Kostulas V, Link H. High levels of IL-10 secreting cells are present in blood in cerebrovascular diseases. Eur J Neurol. 1999; 6: 437–442.[CrossRef][Medline] [Order article via Infotrieve]
14. Perini F, Morra M, Alecci M, Galloni E, Marchi M, Toso V. Temporal profile of serum anti-inflammatory and pro-inflammatory interleukins in acute ischemic stroke patients. Neurol Sci. 2001; 22: 289–296.[CrossRef][Medline] [Order article via Infotrieve]
15. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation. 2001; 104: 746–749.[Abstract/Free Full Text]
16. Adams HP, Bendixen BH, Kappelle LJ, and the TOAST Investigators. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24: 35–41.[Abstract/Free Full Text]
17. Côté R, Hachinski VC, Shurvell BL, Norris JW, Wolfson C. The Canadian Neurological Scale: a preliminary study in acute study. Stroke. 1986; 17: 731–737.[Abstract/Free Full Text]
18. Toni D, Fiorelli M, Zanette EM, Sacchetti ML, Salerno A, Argentino C, Solaro M, Fieschi C. Early spontaneous improvement and deterioration of ischemic stroke patients: a serial study with transcranial Doppler ultrasonography. Stroke. 1998; 29: 1144–1148.[Abstract/Free Full Text]
19. Castillo J, Dávalos A, Lema M, Serena J, Noya M. Glutamate is a marker for cerebral ischemia in cortical but not deep infarcts. Cerebrovasc Dis. 1997; 7: 245–250.
20. Robert C, Vermont J, Bosson JL. Formulas for threshold computations. Comput Biomed Res. 1991; 24: 514–519.[CrossRef][Medline] [Order article via Infotrieve]
21. Revilla M, Obach V, Cervera A, Dávalos A, Castillo J, Chamorro A. A -174G/C polymorphism of the interleukin-6 gene in patients with lacunar infarction. Neurosci Lett. 2002; 324: 29–32.[CrossRef][Medline] [Order article via Infotrieve]
22. Castellanos M, Castillo J, García MM, Leira R, Serena J, Chamorro A, Dávalos A, Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke. 2002; 33: 982–987.[Abstract/Free Full Text]
23. Serena J, Leira R, Castillo J, Pumar JM, Castellanos M, Dávalos A. Neurological deterioration in acute lacunar infarctions: the role of excitatory and inhibitory neurotransmitters. Stroke. 2001; 32: 1154–1161.[Abstract/Free Full Text]
24. Terai S, Hori T, Miake S, Tamaki K, Saishoji A. Mechanism in progressive lacunar infarction: a case report with magnetic resonance imaging. Arch Neurol. 2000; 57: 255–258.[Abstract/Free Full Text]
25. Steinke W, Ley SC. Lacunar stroke is the major cause of progressive motor deficits. Stroke. 2002; 33: 1510–1516.[Abstract/Free Full Text]
26. Grilli M, Barbieri I, Basudev H, Brusa R, Casati C, Lozza G. Interleukin-10 modulates neuronal threshold of vulnerability to ischemic damage. Eur J Neurosci. 2000; 12: 2265–2272.[CrossRef][Medline] [Order article via Infotrieve]
27. Yang Z, Zingarelli B, Szabo C. Crucial role of endogenous interleukin-10 production in myocardial ischemia/reperfusion injury. Circulation. 2000; 101: 1019–1026.[Abstract/Free Full Text]
28. Malefyt RW, Abrams J, Bennet B, Figdor CG, Vries JE. Interleukin-10 inhibits cytokine synthesis by human monocytes. J Exp Med. 1991; 174: 1209–1220.[Abstract/Free Full Text]
29. Silvestre JS, Mallat Z, Tamarat R, Duriez M, Tedgui A, Levy BI. Regulation of matrix metalloproteinase activity in ischemic tissue by interleukin-10: role in ischemia-induced angiogenesis. Circ Res. 2001; 89: 259–264.[Abstract/Free Full Text]
30. Tarkowski E, Rosengren L, Blomstrand C, Jensen C, Ekholm S, Tarkowski A. Intrathecal expression of proteins regulating apoptosis in acute stroke. Stroke. 1999; 30: 321–327.[Abstract/Free Full Text]
31. Gunnett CA, Berg DJ, Faraci FM. Vascular effects of lipopolysaccharide are enhanced in interleukin-10-deficient mice. Stroke. 1999; 30: 2191–2196.[Abstract/Free Full Text]
32. Castillo J, Rama R, Dávalos A. Nitric oxide-related brain damage in acute ischemic stroke. Stroke. 2000; 31: 852–857.[Abstract/Free Full Text]
33. Muntaner J, Alvarez-Sabín J, Molina C, Anglés A, Abilleira S, Arenillas J, Gonzalez MA, Monasterio J. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke. 2001; 32: 1759–1766.[Abstract/Free Full Text]
34. Castillo J, Dávalos A, Alvarez-Sabín J, Pumar JM, Leira R, Silva Y, Montaner J, Kase CS. Molecular signatures of brain injury after intracerebral hemorrhage. Neurology. 2002; 58: 624–629.[Abstract/Free Full Text]
35. Koch W, Kastrati A, Böttiger C, Mehilli J, von Beckerath N, Schömig A. Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis. 2001; 159: 137–144.[CrossRef][Medline] [Order article via Infotrieve]
36. van Exel E, Gussekloo J, de Craen AJM, Bootsma A, Frölich M, Westendorp RGJ. Inflammation and stroke: the Leiden 85-Plus Study. Stroke. 2002; 33: 1135–1138.[Abstract/Free Full Text]
37. Huhn RD, Radwanski E, O’Connell SM, Sturgill MG, Clarke L, Cody RP, Affrime M, Cutler DL. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood. 1996; 87: 699–705.[Abstract/Free Full Text]

This article has been cited by other articles:

				K. Okazaki, M. Kondo, M. Kato, R. Kakinuma, A. Nishida, M. Noda, K. Taniguchi, and H. Kimura Serum Cytokine and Chemokine Profiles in Neonates With Meconium Aspiration Syndrome Pediatrics, April 1, 2008; 121(4): e748 - e753. [Abstract] [Full Text] [PDF]

				S.-T. Lee, K. Chu, K.-H. Jung, S.-J. Kim, D.-H. Kim, K.-M. Kang, N. H. Hong, J.-H. Kim, J.-J. Ban, H.-K. Park, et al. Anti-inflammatory mechanism of intravascular neural stem cell transplantation in haemorrhagic stroke Brain, March 1, 2008; 131(3): 616 - 629. [Abstract] [Full Text] [PDF]

				A. Chamorro, X. Urra, and A. M. Planas Response to Letter by Emsley et al Stroke, January 1, 2008; 39(1): e8 - e8. [Full Text] [PDF]

				A. Chamorro, X. Urra, and A. M. Planas Infection After Acute Ischemic Stroke: A Manifestation of Brain-Induced Immunodepression Stroke, March 1, 2007; 38(3): 1097 - 1103. [Abstract] [Full Text] [PDF]

				A Chamorro, S Amaro, M Vargas, V Obach, A Cervera, F Torres, and A M Planas Interleukin 10, monocytes and increased risk of early infection in ischaemic stroke. J. Neurol. Neurosurg. Psychiatry, November 1, 2006; 77(11): 1279 - 1281. [Abstract] [Full Text] [PDF]

				K. B. Holven, B. Halvorsen, V. Bjerkeli, J. K. Damas, K. Retterstol, L. Morkrid, L. Ose, P. Aukrust, and M. S. Nenseter Impaired Inhibitory Effect of Interleukin-10 on the Balance Between Matrix Metalloproteinase-9 and Its Inhibitor in Mononuclear Cells From Hyperhomocysteinemic Subjects Stroke, July 1, 2006; 37(7): 1731 - 1736. [Abstract] [Full Text] [PDF]

				J. R. S. Day, R. C. Landis, and K. M. Taylor Aprotinin and the protease-activated receptor 1 thrombin receptor: antithrombosis, inflammation, and stroke reduction. Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2006; 10(2): 132 - 142. [Abstract] [PDF]

				D. Giuliani, C. Mioni, D. Altavilla, S. Leone, C. Bazzani, L. Minutoli, A. Bitto, M.-M. Cainazzo, H. Marini, D. Zaffe, et al. Both Early and Delayed Treatment with Melanocortin 4 Receptor-Stimulating Melanocortins Produces Neuroprotection in Cerebral Ischemia Endocrinology, March 1, 2006; 147(3): 1126 - 1135. [Abstract] [Full Text] [PDF]

				J. R.S. Day, K. M. Taylor, E. A. Lidington, J. C. Mason, D. O. Haskard, A. M. Randi, and R. C. Landis Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1 J. Thorac. Cardiovasc. Surg., January 1, 2006; 131(1): 21 - 27. [Abstract] [Full Text] [PDF]

				M. L. Kielar, R. John, M. Bennett, J. A. Richardson, J. M. Shelton, L. Chen, D. R. Jeyarajah, X. J. Zhou, H. Zhou, B. Chiquett, et al. Maladaptive Role of IL-6 in Ischemic Acute Renal Failure J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3315 - 3325. [Abstract] [Full Text] [PDF]

				M. Blanco, M. A. Moro, A. Davalos, R. Leira, M. Castellanos, J. Serena, J. Vivancos, M. Rodriguez-Yanez, I. Lizasoain, and J. Castillo Increased Plasma Levels of 15-Deoxy {Delta} Prostaglandin J2 Are Associated With Good Outcome in Acute Atherothrombotic Ischemic Stroke Stroke, June 1, 2005; 36(6): 1189 - 1194. [Abstract] [Full Text] [PDF]

				D. Frenkel, Z. Huang, R. Maron, D. N. Koldzic, W. W. Hancock, M. A. Moskowitz, and H. L. Weiner Nasal Vaccination with Myelin Oligodendrocyte Glycoprotein Reduces Stroke Size by Inducing IL-10-Producing CD4+ T Cells J. Immunol., December 15, 2003; 171(12): 6549 - 6555. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 34/3/671    most recent 01.STR.0000057976.53301.69v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vila, N. Articles by Chamorro, A. Search for Related Content PubMed PubMed Citation Articles by Vila, N. Articles by Chamorro, A. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Stroke Related Collections Acute Cerebral Infarction Growth factors/cytokines Cerebral Lacunes